Eczema and Atopic Dermatitis Clinical Trials 2026: New Biologics, JAK Inhibitors & Itch Treatments

Atopic dermatitis was, for most of medical history, treated as a skin condition — topical corticosteroids, moisturizers, and the unsatisfying advice to "avoid triggers." The recognition that moderate-to-severe AD is a systemic type 2 inflammatory disease driven by IL-4, IL-13, and IL-31 dysregulation transformed the research agenda. Dupilumab's approval in 2017 validated that approach, and the 2026 pipeline has deepened it significantly: multiple JAK inhibitors approved, tralokinumab and lebrikizumab available, and trials now asking whether early biologic intervention in children can modify disease course rather than just control it.

The Atopic Dermatitis Treatment Landscape in 2026

Dupilumab (Dupixent) — approved in 2017 — transformed atopic dermatitis treatment by blocking IL-4/IL-13 signalling. It remains the most widely used biologic, but approximately 30–40% of patients are partial responders or non-responders. This gap has driven intense clinical development:

• IL-13 selective inhibitors: Tralokinumab and lebrikizumab specifically block IL-13 (not IL-4), with comparable efficacy to dupilumab and injection site reaction advantages
• Oral JAK inhibitors: Abrocitinib, upadacitinib, and baricitinib offer rapid response (significant itch relief within days) but require monitoring for cardiovascular risk and thrombosis
• Nemolizumab: Blocks IL-31 receptor — directly targeting the itch pathway rather than inflammation. FDA-approved in 2024, still in trials for new indications
• Next-generation biologics: OX40/OX40L pathway (rocatinlimab, amlitelimab), TSLP targeting, IL-33 antibodies — for patients who fail dupilumab or JAK inhibitors

Key Trials Recruiting in 2026

Amlitelimab (OX40L Antibody) — Phase 3 AVOLVE Programme

Sanofi/Regeneron's amlitelimab blocks OX40 ligand — a central T-cell activation signal in atopic dermatitis. AVOLVE-1 and AVOLVE-2 Phase 3 trials are enrolling adults with moderate-to-severe AD who have failed or are intolerant to dupilumab. Phase 2 showed 46% EASI-75 response at 16 weeks. Key advantage: monthly dosing and early data suggesting potential for disease modification (extended remission after stopping). Eligibility: EASI ≥16, IGA ≥3, documented dupilumab failure.

Nemolizumab Combination Studies — Phase 3

Following FDA approval of nemolizumab (Nemluvio) in 2024 for moderate-to-severe AD with inadequate response to topical treatments, 2026 trials are investigating nemolizumab plus topical corticosteroids in adolescents (12–17), long-term itch control and sleep quality, and combination with dupilumab for dual-pathway blockade. Itch is the primary driver of quality-of-life impairment — trials specifically measuring Worst Pruritus NRS ≥7 at baseline.

JAK Inhibitor Head-to-Head Studies

With three oral JAK inhibitors approved in the US and EU, head-to-head comparisons against dupilumab are ongoing. JADE COMPARE (abrocitinib vs. dupilumab) is being extended. New trials compare abrocitinib vs. upadacitinib directly. Key patient selection: prior biologic failure, need for rapid itch relief (within 2 weeks), and patients who prefer oral over injectable therapy. Safety monitoring includes CBC, lipid panels, and cardiovascular risk stratification.

Pediatric and Adolescent Trials

Atopic dermatitis is most common in children (prevalence 15–20% in children vs. 2–5% in adults). Several trials specifically recruit pediatric populations: dupilumab in infants ages 6 months–5 years (extension studies), tralokinumab in adolescents 12–17, and ruxolitinib cream (Opzelura) in children ages 2–11 for mild-to-moderate disease. Parents should note that consent and assent requirements differ for minors.

Topical and Non-Biologic Innovations

Not all trials require injections or oral systemic drugs. Active studies in 2026 include: tapinarof cream (Vtama) extension to atopic dermatitis after psoriasis approval, crisaborole PDE4 inhibitor combination studies, and several microbiome-modulating interventions targeting Staphylococcus aureus skin colonisation. These trials often have fewer exclusion criteria and are particularly relevant for patients with mild-to-moderate disease.

Eligibility — What Most Trials Require

How to Measure Your Eczema Severity Before Applying

Trials use standardised scoring tools that you should familiarise yourself with before contacting a study site:

• EASI (Eczema Area and Severity Index): Body surface area × intensity scores across 4 body regions. Score 0–72. Moderate = 7.1–21.0; severe = 21.1–72.
• IGA (Investigator Global Assessment): 0 (clear) to 4 (severe). Most trials require IGA ≥3 at screening.
• Pruritus NRS: 0–10 itch scale. Many itch-targeted trials require NRS ≥7 (worst 24-hour itch).
• DLQI (Dermatology Life Quality Index): Quality-of-life impact scoring. Some trials use this as a secondary endpoint.

Your dermatologist can formally score these at a pre-screening visit. Having recent documentation of inadequate response to topical treatments is the most important eligibility factor for most trials.

What to Expect in an Atopic Dermatitis Trial

Screening period (2–4 weeks)

Washout of prior treatments, baseline photographs, scoring, blood tests, and possibly skin biopsies (in mechanistic sub-studies). During washout, only emollients and low-potency topicals permitted.

Treatment period (16–52 weeks)

Most Phase 3 trials have a 16-week placebo-controlled period, followed by an open-label extension. Biologic injections are typically every 2–4 weeks (self-administered, after training). JAK inhibitor trials involve daily oral dosing with regular blood monitoring.

Endpoints

Primary endpoints are typically EASI-75 (75% improvement from baseline) and IGA 0/1 (clear or almost clear) at 16 weeks. Secondary endpoints include itch NRS, sleep disturbance, and quality of life measures. Early response is assessed at week 4 and week 8.